Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sanara MedTech (SMTI)
NASDAQ:SMTI
Holding SMTI?
Track your performance easily
Earnings Data
Report Date
Mar 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.03Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 26, 2020
|% Change Since: 4.94%
|Next Earnings Date:Nov 14, 2019
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and strategic investments, notably in ChemoMouthpiece, alongside ongoing expansion efforts. However, these positives were tempered by a substantial net loss increase, higher SG&A expenses, and rising interest costs.Company Guidance
During the Sanara MedTech Q3 2024 earnings call, several key financial metrics and strategic initiatives were discussed. The company reported a net revenue of $21.7 million, reflecting a 35% year-over-year increase, marking their 12th consecutive record revenue quarter. Adjusted EBITDA improved to $800,000, up from $300,000 in Q3 2023. The Surgical segment posted a $2.6 million segmented EBITDA for the quarter, despite a net loss of $200,000. Sanara's strategic focus includes continued investment in the Tissue Health Plus (THP) platform, with plans for a mid-2025 commercial launch. Additionally, the company invested $5 million in ChemoMouthpiece, LLC, acquiring a significant ownership stake and securing an exclusive U.S. distribution agreement. This aligns with their broader wound and skin care strategy. The company also expanded its market presence, with products sold in over 1,200 hospitals across 34 states and contracted in more than 4,000 facilities. Overall, Sanara MedTech remains committed to growth through strategic partnerships, innovation in wound care, and potential M&A opportunities.Record Revenue Growth
The company generated $21.7 million in net revenue, a 35% increase year-over-year, marking the 12th consecutive record revenue quarter.
Improved EBITDA Results
Sanara reported an adjusted EBITDA of $800,000 in Q3 2024 compared to $300,000 in Q3 2023.
Expansion in Facility Contracts
Sanara products were sold in over 1,200 hospitals across 34 states and contracted to be sold in more than 4,000 facilities.
Strong Growth in Soft Tissue Product Sales
Soft tissue product sales grew from $13.6 million in Q3 2023 to $18.9 million in Q3 2024.
Introduction of ChemoMouthpiece
Sanara invested $5 million for a stake in ChemoMouthpiece, LLC and signed an exclusive U.S. distribution agreement.
---
SMTI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SMTI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $34.60 | $37.22 | +7.57% |
| Aug 12, 2024 | $27.83 | $32.04 | +15.13% |
| May 13, 2024 | $31.42 | $29.28 | -6.81% |
| Mar 25, 2024 | $36.25 | $36.75 | +1.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sanara MedTech (SMTI) report earnings?
Sanara MedTech (SMTI) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
What is Sanara MedTech (SMTI) earnings time?
Sanara MedTech (SMTI) earnings time is at Mar 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SMTI EPS forecast?
SMTI EPS forecast for the fiscal quarter 2024 (Q4) is -0.12.
---